Kymera IPO Presentation Deck

KYMERA IND IRAKIMID Development in MYD88 Mutant DLBCL Target Date H2 2021 H2 2022 Phase 1 B Cell Lymphomas Milestones IND and Study Start Clinical POC • Multi-center dose escalation study (US) B cell lymphomas • Safety, tolerability, PK and PD (POB) and preliminary clinical activity • P1b Expansion cohort in DLBCL (MYD88-mut and-wt) with and without CNS involvement at MTD • Option to amend protocol to explore select combinations . Clinical and biomarker endpoints POC

View entire presentation